We’re more a calling than a company.

One of the most respected leaders at the forefront of genome engineering technologies, Kevin specializes in turning rapidly commercializing early-stage ideas into successful ventures. He previously cofounded and built two groundbreaking companies in the genome reading space, QuantaLife and 10X Genomics.

A mechanical engineer by trade, he is a true tool-builder at heart, committed to best-in-class solutions for biologists. Originally from California, he earned his Bachelor’s and Master’s degrees in Mechanical Engineering from University of California, Santa Barbara and his Doctorate in Mechanical Engineering from Stanford University.

A 25-year veteran of life sciences commercial operations, Jason leverages his executive experience at leading biotech companies to oversee Inscripta’s sales, marketing, business development and customer support operations. 

Jason has developed product and customer engagement strategies for some of the industry’s most preeminent brands, most recently at QIAGEN, as Vice President of the life science business area. Prior to QIAGEN, Jason developed commercialization growth strategies at Ingenuity Systems, a leading bioinformatics company acquired by QIAGEN in 2013. He has also held senior leadership roles at Sigma-Aldrich (SIAL), Life Technologies (LIFE), Affymetrix (AFFX), and Promega Corporation.

Having led teams that developed and commercialized foundational reagent and consumable products for Illumina’s microarray and next generation sequencing platforms, Michael brings over 20 years of experience in technology and product development. 

Prior to Illumina, Michael held positions at BioSite Diagnostics and the University of California. He brings a broad background in measurement science, surface modification, process engineering, device fabrication, and cross-functional team leadership. He holds a PhD in Chemical Physics from the University of California, San Diego.

Specializing in product protection strategies, transactional law and patent enforcement for life science companies, Dianna was previously Senior Vice President of Intellectual Property and Legal Affairs at Ariosa Diagnostics, Inc.(acquired by Roche Molecular Systems in 2015). She has been legal and IP counsel for various companies including Complete Genomics, Cambridge Antibody Technology (a wholly-owned subsidiary of AstraZeneca) and Élan Pharmaceuticals. In 2002, Dianna cofounded the Australian Stem Cell Centre (ASCC) in Melbourne, Australia, the first Australian Biotechnology Centre of Excellence. 

Dianna holds a B.S. in Art History from Johns Hopkins, a Ph.D. in Genetics from Yale University, and a J.D. from Stanford Law School.

Having held numerous leadership and financial roles in the biotechnology and information technology industries, Ron brings more than 25 years of industry experience to Inscripta. Prior to joining Inscripta, he spent 13 years with Illumina, serving as Vice President of Finance and Chief of Staff in Operations. 

Before joining Illumina, he held financial leadership roles at Memec, LLC, a designer and distributor of semiconductors, and DJ Orthopedics, LLC, a medical device manufacturer and distributor. He holds an MBA from Pepperdine University and a Bachelor’s degree in Quantitative Economics from the University of California, San Diego.

Recognized for his ability to build and expand global business capabilities by launching, stabilizing and scaling innovative products for early-stage and mature companies, Tom is a notable leader in the life science and technology sectors. Previously, Tom cofounded Solana BioSciences after serving as the Vice President of Operations at Illumina. 

Tom earned his Bachelor’s degree in Business Administration and Finance from University of Southern California and his MBA from the Kellogg School of Management. He currently chairs the New Children’s Museum Board of Directors in San Diego.

With more than 25 years in research and development leadership, and having built world-class R&D teams, Jim most recently served as Senior Vice President of R&D at Codexis, Inc., where he oversaw the development of more than 50 enzymes for drug manufacture, nutrition, biotherapeutics, and molecular diagnostics. He also led development of the best-in-class CodeEvolver^® protein engineering technology and licensed it to major pharmaceutical companies in multimillion-dollar deals. Prior to his time at Codexis, Dr. Lalonde held a leadership role in chemical development at Altus Biologics. 

Originally a Senior Scientist at Vista Chemical Company, he holds a Bachelor’s degree in Chemistry from Lakehead University and a PhD in Organic Chemistry from Texas A&M University.